Kevan M. Shokat, PhD: Drugging the Elusive KRAS
Dr. Shokat shifted the paradigm of targeted cancer therapy by drugging an “undruggable” protein and paving the way for future advances.
Dr. Shokat shifted the paradigm of targeted cancer therapy by drugging an “undruggable” protein and paving the way for future advances.
A career development grant from the AACR helped Luisa Escobar-Hoyos, MSC, PhD, earn two major federal grants to further develop her research.
An AACR fellowship helped a young pediatrician become a physician-scientist, using clinical insights to inform the search for new cancer therapeutics in the laboratory. As a pediatric fellow in the mid-1990s, Michael Jensen, MD,...
Tumors are “born to be bad” with metastatic potential present from the start, spreading to other organs when the original malignancy is the size of a poppy seed, she says. As a teenager, Christina...
An early collaboration between AACR Fellows Joseph F. Fraumeni, MD, and Frederick P. Li, MD, defined one of the first cancer predisposition syndromes linked to the most commonly mutated gene across all cancer types. ...
A career development grant from the AACR initiated the development of a model to help understand one of the deadliest and most difficult-to-treat types of cancer.
“It worked better than our wildest dreams,” Dr. Diaz said of a therapeutic approach that uses a tumor biomarker to identify patients likely to respond to immunotherapy. A cancer diagnosis comes with a multitude...
Dr. Patricia LoRusso’s parents Both died of cancer when she was a teenager, inspiring her to become an oncologist and focus on developing new treatments for people with cancer. Patricia LoRusso, DO, deals with...